Guideline for the treatment of mixed phenotype acute leukemia

Share This Post

A study conducted at the Los Angeles Children ‘s Hospital is providing the best treatment for a rare invasive leukemia called mixed phenotype acute leukemia (MPAL).

This study (a 20-year quantitative synthesis of the scientific literature) found that treatment of MPAL with a low-toxicity regimen is associated with a clear benefit of remission and possible long-term survival. These findings were published in the online journal “Leukemia” on February 27, 2018.

MPAL accounts for 2% -5% of leukemia cases, which is historically difficult to treat, and the 5-year survival rate is less than 50%. The disease affects children and adults and is characterized by two common forms of leukemia: acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML).

The physician must decide whether to use ALL or AML, or a mixture of the two methods. There is no clear consensus on which method is best. Because this disease is very rare, thousands of patients have not been clinically tested to determine the best treatment plan. Instead, many small, isolated, and often conflicting case reports have been published in widely distributed magazines around the world .

In order to better understand existing research and provide doctors with clearer treatment guidance, Orgel and the CHLA research team conducted the first observational systematic review and meta-analysis of MPAL. The team eventually narrowed the list to 252 related papers from 33 countries, involving 1,499 patients. Their key finding: Patients who were initially treated with ALL (patients with significantly lower toxicity) were 3 to 5 times more likely to achieve complete remission than patients who were treated with AML. The patients who received mixed therapy performed the worst.

The study highlights the important need for clinical trials to determine the best treatment for MPAL and helps promote the treatment of this rare disease.

Website |  + posts

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
Cancer

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor

The FDA approved vimseltinib for symptomatic tenosynovial giant cell tumor (TGCT) in patients who cannot be treated with surgery. The oral CSF1R inhibitor blocks tumor growth and alleviates symptoms, providing a surgery-free way to control TGCT. The approval is based on clinical trial evidence of substantial tumor shrinkage and symptom relief. The approval is a significant step forward in TGCT treatment, enhancing the quality of life for these patients.

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma
Blood cancer

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma

The FDA approved brentuximab vedotin in combination with lenalidomide and rituximab to treat relapsed or refractory large B-cell lymphoma (LBCL). The combination represents a new option for treatment after failure of initial therapies. The approval follows the presentation of data from clinical trials showing that this combination improved patient outcomes. This combination is a new strategy in the management of LBCL and provides a greater number of available treatments for those with few choices.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟